Sampath Kumar Anandan

Summary

Publications

  1. doi request reprint Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N'-diaryl urea inhibitors of soluble epoxide hydrolase
    Sampath Kumar Anandan
    Arete Therapeutics, Inc, 7000 Shoreline Court, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 20:2740-4. 2010
  2. pmc 1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia
    Sampath Kumar Anandan
    Arete Therapeutics, Inc, 7000 Shoreline Court, South San Francisco, CA 94080, United States
    Bioorg Med Chem Lett 21:983-8. 2011
  3. doi request reprint Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension
    Le Ning Zhang
    Arete Therapeutics Inc, South San Francisco, CA 94080, USA
    Eur J Pharmacol 654:68-74. 2011
  4. doi request reprint Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors
    Sampath Kumar Anandan
    Arete Therapeutics, Inc, 3912 Trust Way, Hayward, CA 94545, USA
    Bioorg Med Chem Lett 19:1066-70. 2009
  5. doi request reprint Unsymmetrical non-adamantyl N,N'-diaryl urea and amide inhibitors of soluble expoxide hydrolase
    Sampath Kumar Anandan
    Arete Therapeutics, Inc, 3912 Trust Way, Hayward, CA 94545, USA
    Bioorg Med Chem Lett 19:4259-63. 2009

Detail Information

Publications5

  1. doi request reprint Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N'-diaryl urea inhibitors of soluble epoxide hydrolase
    Sampath Kumar Anandan
    Arete Therapeutics, Inc, 7000 Shoreline Court, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 20:2740-4. 2010
    ....
  2. pmc 1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia
    Sampath Kumar Anandan
    Arete Therapeutics, Inc, 7000 Shoreline Court, South San Francisco, CA 94080, United States
    Bioorg Med Chem Lett 21:983-8. 2011
    ..These effects were dose-dependent and well correlated with inhibition of the sEH activity in whole blood, consistent with a role of sEH in the observed pharmacology in rodents...
  3. doi request reprint Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension
    Le Ning Zhang
    Arete Therapeutics Inc, South San Francisco, CA 94080, USA
    Eur J Pharmacol 654:68-74. 2011
    ..Thus, preserving vasodilator EETs by inhibition of s-EH may be of therapeutic benefit by improving endothelial function in cardiometabolic diseases...
  4. doi request reprint Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors
    Sampath Kumar Anandan
    Arete Therapeutics, Inc, 3912 Trust Way, Hayward, CA 94545, USA
    Bioorg Med Chem Lett 19:1066-70. 2009
    ..The hydroxyamide moiety was identified as a novel pharmacophore affording potency comparable to urea...
  5. doi request reprint Unsymmetrical non-adamantyl N,N'-diaryl urea and amide inhibitors of soluble expoxide hydrolase
    Sampath Kumar Anandan
    Arete Therapeutics, Inc, 3912 Trust Way, Hayward, CA 94545, USA
    Bioorg Med Chem Lett 19:4259-63. 2009
    ....